Navigation Links
Foot Deformity Could Be Corrected With Minimal Surgery

A treatment developed by a pediatric orthopedic surgeon has shown early success in correcting the foot deformity in children. The treatment for rigid flatfoot//, which once required extensive surgery, can now be corrected with minimal surgery.

Congenital vertical talus (CVT), or "rocker-bottom flat foot," occurs in about 1 in 10,000 live births. Left untreated, the patient would walk on the inside of the ankle rather than the bottom of the foot, resulting in pain and disability. CVT afflicts both healthy children and those with genetic birth defects and neuromuscular disorders.

Matthew B. Dobbs, M.D., who performs surgeries at St. Louis Children's Hospital, developed a treatment for CVT that involves gently manipulating the foot and applying long leg casts weekly for four to six weeks to gradually correct the deformity. After the casting period, Dobbs and his colleagues take an X-ray to determine the success of the correction.

"Much of the correction is achieved with casting alone," says Dobbs, associate professor of orthopaedic surgery at the School of Medicine. "In the cases where we are not able to reach full correction with casting, we reach the rest of the correction with a minimally invasive surgery. This type of surgery is very small compared to the extensive release surgery that has been done in the past."

In the minor surgical procedure, Dobbs inserts a small pin into a joint in the foot where it meets the ankle to hold the correct position for about two months. After the casting treatments or the surgical pinning, CVT patients wear a nighttime brace for several years to prevent recurrence.

Details about the treatment in 11 patients with CVT, or a total of 19 feet, are discussed in the March 2007 issue of The Journal of Bone and Joint Surgery.

His method has caught the attention of pediatric orthopaedic surgeons worldwide, and he is training other surgeons in the United States and inte
'"/>




Page: 1 2

Related medicine news :

1. Shanghai Doctors Clueless About Babys Deformity
2. Children of Bhopal Gas Victims Suffer from Deformity
3. Lean Protein Could Be Key to Obesity Drugs
4. Nasal Spray Could Take Drugs Direct to Brain.
5. Nasal Spray Could Take Drugs Directly to Brain
6. Oxygen Usage During Exercise Could Indicate Heart Problems
7. Ultrasound Screening Could Improve The Outcome Of Critically ill Patients
8. Anger Could Be Linked To Weight Gain
9. A Seizure Late In Life Could be A Stroke Warning
10. New Findings Could Reduce The Extent Of Spinal Cord Injuries
11. Could There Be A Link Between Famine and Breast Cancer ?
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Foot Deformity Could Corrected With Minimal Surgery

(Date:5/21/2013)... CA (PRWEB) May 21, 2013 DISCcert ... materials showing how to use 17 DISC applications at ... is a natural progression. , The July 25 & ... the top 17 ways of applying DISC. The time-tested, ... certified graduates. The user-friendly DISC training materials ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... to protecting the rights of victims injured by defective ... Journal of Bone & Joint Surgery on May 15, ... can be used to identify complications that occur in ... any symptoms of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) ...
(Date:5/21/2013)... The Orsiro stent, which is a novel stent ... non-inferiority to the Xience Prime everolimus-eluting stent for ... loss at nine months in the results of ... , The BIOFLOW-II substudy used intravascular ultrasound (IVUS) ... neointimal hyperplasia and stent apposition at nine months ...
(Date:5/21/2013)... Hillsboro, OR (PRWEB) May 21, 2013 ... curing systems at the 20th Annual IMI European ... As a proven market leader, Phoseon continues to invest ... while accelerating the adoption of UV LED curing in ... of product families on the market offering both air ...
(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...
Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2
... The Lancet Supports Cardio-Protective Potential of Aleglitazar - , ... will start Phase III clinical investigations for aleglitazar, its innovative ... morbidity and mortality in high risk patients with type 2 ... II SYNCHRONY study published today in The Lancet(1) ...
... , Customizable Survival Kit Offers One Stop for ... Local Healthcare Market Drivers and Health Plan Trends ... a leading provider of managed care market intelligence, ... shifts in membership at the state level than ...
... the company that will become public from the planned ... today filed a second amendment to its Form 10 ... that includes information about its post-spin board of directors ... under a consent decree for its Alaris(R) infusion products. ...
... United Spinal Association ( www.UnitedSpinal.org ) presents the ... ) , the region,s premiere lifestyle-enhancing Expo designed to ... aging Americans. , , The Independence Expo will ... at the Suffolk Community College Sports & Exhibition Complex in ...
... PSI-7851 was generally safe and well tolerated in Phase 1a ... results from single ascending and multiple ascending dose trials are ... June 9 Pharmasset, Inc. (Nasdaq: VRUS ) ... study and begun dosing in a multiple ascending dose trial ...
... ... its Multilayer Aneurysm Repair System (MARS) has received CE Mark approval for treating patients ... ... announced today that it has received CE Mark approval for the commercial sale of ...
Cached Medicine News:Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 2Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 3Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 4Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 5Health News:Commercial Pharmacy Benefit Enrollment Experiencing Greater Shifts in Florida than Commercial Medical Benefit Enrollment 2Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 2Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 3Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 4Health News:United Spinal Association Presents The 2009 Independence Expo: Improving Life for the Disabled and the Aging 2Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 2Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 3Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 4Health News:Cardiatis Multilayer Aneurysm Repair System, MARS, Receives CE Mark Approval for Treating Peripheral Aneurysms 2
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May ... SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ... published online the positive Phase 2a study results of ... is an investigational monoclonal antibody targeting the alpha subunit ... signaling of both IL-4 and IL-13, drivers of Th2 ...
(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...
(Date:5/21/2013)... NEW YORK , May 21, 2013 ... market research report is available in its ... Changing Regulatory and Reimbursement Scenario for Medical ... http://www.reportlinker.com/p01188015/Changing-Regulatory-and-Reimbursement-Scenario-for-Medical-Devices-in-the-US-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging   ... Devices in the US Market ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... 14, 2011 /PRNewswire / -- Nephros, Inc. (OTC Bulletin Board: ... three months ended September 30, 2011. Recent ... associated with Rights Offering to be exercised; Received initial ... Hemodiafiltration System in U.S. Financial ...
... 14, 2011 Landauer, Inc. (NYSE: LDR ... radiation monitoring and the leading domestic provider of outsourced ... all of the outstanding equity interests of  IZI Medical ... a purchase price of approximately $93 million. IZI Medical ...
Cached Medicine Technology:Nephros Reports Third Quarter 2011 Financial Results 2Nephros Reports Third Quarter 2011 Financial Results 3Nephros Reports Third Quarter 2011 Financial Results 4Nephros Reports Third Quarter 2011 Financial Results 5Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 2Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 3Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 4Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 5Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 6
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • Not available with casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Medicine Products: